A carregar...
Safety and efficacy of daclatasvir in the management of patients with chronic hepatitis C
Daclatasvir (Daklinza™), a new oral direct-acting antiviral, is an inhibitor of hepatitis C virus NS5A protein and has recently been approved in the United States, Europe and Japan in chronic hepatitis C. It shows potent pangenotypic activity and moderately high genetic barrier to resistance improvi...
Na minha lista:
| Publicado no: | Ann Gastroenterol |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Hellenic Society of Gastroenterology
2016
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4923813/ https://ncbi.nlm.nih.gov/pubmed/27366028 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.20524/aog.2016.0041 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|